

## **Title**

Evidence of Cardiac Involvement in the Fetal Inflammatory Response Syndrome: Disruption of Gene Networks Programming Cardiac Development in Nonhuman Primates

## **Authors and Affiliations**

Timothy MITCHELL, MD\*; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA

Mr. James W. MACDONALD, MSc; Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA

Ms. Sengkeo SRINOUANPRANCHANH, BS; Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA

Theodor K. BAMMLER, PhD; Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA

Sean MERILLAT, BS; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA

Erica BOLDENOW, PhD; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA

Michelle COLEMAN, PhD; Department of Pediatrics, University of Washington, Seattle, WA

Kathy Agnew, BS; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA

Audrey BALDESSARI, DVM; Washington National Primate Research Center, University

of Washington, Seattle, WA

Jennifer E. STENCEL-BAERENWALD, PhD; Center for Innate Immunity and Immune Disease and the Department of Immunology, University of Washington, Seattle, WA

Jennifer TISONCIK-GO, PhD; Center for Innate Immunity and Immune Disease and the Department of Immunology, University of Washington, Seattle, WA

Richard R. GREEN, PhD; Center for Innate Immunity and Immune Disease and the Department of Immunology, University of Washington, Seattle, WA

Michael J. GALE, Jr., PhD; Center for Innate Immunity and Immune Disease and the Departments of Immunology and Global Health, University of Washington, Seattle, WA

Lakshmi RAJAGOPAL\*\*, PhD; Department of Pediatrics, University of Washington and Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA

Kristina M. ADAMS WALDORF\*\*, MD; Departments of Obstetrics & Gynecology and Global Health and the Center for Innate Immunity and Immune Disease at the University of Washington, Seattle, WA, USA and Sahlgrenska Academy, Gothenburg, Sweden

\*Current Address for Dr. Mitchell: Center for Genetics and Maternal-Fetal Medicine, 3355 Riverbend Dr. Suite #210, Springfield OR 97477.

\*\*co-corresponding authors

The authors report no conflict of interest.

Research reported in this publication was supported by the March of Dimes (21-FY08-562), National Institute of Allergy and Infectious Diseases and National Center for

Research Resources of the National Institute of Health under award numbers [R01AI100989, R01AI33976, R01AI112619, R21AI09222, K08AI067910, P30HD002274] and the University of Washington Department of Obstetrics & Gynecology. This project was also supported by the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health (P51OD010425) through the Washington National Primate Research Center, as well as the UW Intellectual and Developmental Disabilities Research Center (5U54HD083091-04) funded by the Eunice Kennedy Shriver National Institute of Child & Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. The sponsors had no role in the study design, collection, analysis and interpretation of the data, writing of the report or the decision to submit the article for publication.

These findings were presented at the 63<sup>rd</sup> Meeting of the Society for Reproductive Investigation in Montreal, Canada held March 16-19, 2016.

Correspondence:

Kristina Adams Waldorf, M.D., University of Washington, Box 356460, Seattle, WA 98195, Tel: 206-543-5555, Fax: 206-543-3915, E-mail: [adamsk@uw.edu](mailto:adamsk@uw.edu)

Lakshmi Rajagopal, Ph.D., Seattle Childrens Research Institute, Seattle, WA 98101, Tel: 206-884-7336, Fax: 206-884-7311, Email: [lakshmi.rajagopal@seattlechildrens.org](mailto:lakshmi.rajagopal@seattlechildrens.org)

Word count (abstract): 382

Word count (main text excluding methods and references): 2,710

**Summary Statement**

In a nonhuman primate model of intraamniotic infection, preterm labor and severe fetal inflammation are associated with downregulation of cardiac morphogenesis and vasculogenesis gene networks.

**Short Version of the Title**

Disruption of fetal cardiac gene networks with fetal infection and inflammation

1 **Abstract**

2

3 **Background:** The majority of early preterm births are associated with intraamniotic  
4 infection and inflammation, which can lead to systemic inflammation in the fetus. The  
5 fetal inflammatory response syndrome describes elevations in the fetal interleukin-6 (IL-  
6 6) level, which is a marker for inflammation and fetal organ injury. Understanding the  
7 effects of inflammation on fetal cardiac development may lead to insight into the fetal  
8 origins of adult cardiovascular disease.

9 **Objective:** To determine whether the fetal inflammatory response syndrome is  
10 associated with disruptions in gene networks programming fetal cardiac development.

11 **Study Design:** We obtained fetal cardiac tissue following necropsy from a well-  
12 described pregnant nonhuman primate model (pigtail macaque, *Macaca nemestrina*) of  
13 intrauterine infection (N=5) and controls (N=5). Cases with the fetal inflammatory  
14 response syndrome (fetal plasma IL-6 >11 pg/ml) were induced by either choriodecidual  
15 inoculation of a hypervirulent Group B Streptococcus strain (N=4) or intraamniotic  
16 inoculation of *Escherichia coli* (N=1). RNA and protein were extracted from fetal hearts  
17 and profiled by microarray and Luminex for cytokine analysis, respectively. Results  
18 were validated by quantitative RT-PCR. Statistical and bioinformatics analyses included  
19 single gene analysis, Gene Set Analysis, Ingenuity Pathway Analysis, and Wilcoxon  
20 rank sum.

21 **Results:** Severe fetal inflammation developed in the context of intraamniotic infection  
22 and a disseminated bacterial infection in the fetus. IL-6 and IL-8 in fetal cardiac tissues  
23 were significantly elevated in fetal inflammatory response syndrome cases versus

24 controls ( $p < 0.05$ ). A total of 609 probe sets were differentially expressed ( $> 1.5$ -fold  
25 change,  $p < 0.05$ ) in the fetal heart (ANOVA). Altered expression of select genes was  
26 validated by qRT-PCR including several with known functions in cardiac injury,  
27 morphogenesis, angiogenesis and tissue remodeling (e.g. ACE2, STEAP4, NPPA and  
28 SFRP4; all  $p < 0.05$ ). Multiple gene sets and pathways involved in cardiac  
29 morphogenesis and vasculogenesis were significantly downregulated by gene set and  
30 ingenuity pathway analysis (hallmark TGF beta signaling, cellular morphogenesis during  
31 differentiation, morphology of cardiovascular system, all  $p < 0.05$ ).

32 **Conclusion:** Disruption of gene networks for cardiac morphogenesis and  
33 vasculogenesis occurred in the preterm fetal heart of nonhuman primates with preterm  
34 labor, intraamniotic infection and severe fetal inflammation. Inflammatory injury to the  
35 fetal heart *in utero* may contribute to the development of heart disease later in life.  
36 Development of preterm labor therapeutics must also target fetal inflammation to lessen  
37 organ injury and potential long-term effects on cardiac function.

38

### 39 **Key Words**

40 Animal model, cardiac, chorioamnionitis, development, *Escherichia coli*, E. coli, fetal  
41 sepsis, fetal inflammatory response syndrome, fetus, Group B Streptococcus, GBS,  
42 heart, intrauterine infection, *Macaca nemestrina*, monkey, morphogenesis, neonate,  
43 pigtail macaque, pregnancy, preterm labor, preterm birth, sepsis, vasculogenesis.

44

45

### 46 **Glossary of Terms**

- 47 ACE2, Angiotensin I converting enzyme 2
- 48 ANGPTL7, Angiopoietin-like 7
- 49 ANP, atrial natriuretic peptide
- 50 cDNA, complementary DNA
- 51 CFTR, Cystic fibrosis transmembrane conductance regulator
- 52 *E. coli*, *Escherichia coli*
- 53 FAM69C, Family with sequence similarity 9, member c
- 54 GBS, Group B Streptococcus
- 55 GRIA3, Glutamate Receptor, ionotropic, AMPA3
- 56 IRX4, Iroquois homeobox 4
- 57 IL-6, interleukin 6
- 58 IL-8, interleukin 8
- 59 MAL2, Mal T-cell differentiation protein 2
- 60 MYL7, Myosin regulatory light chain 2, atrial isoform-like
- 61 NPPA, Natriuretic peptide A
- 62 qRT-PCR, quantitative reverse transcriptase polymerase chain reaction
- 63 SFRP4, Secreted frizzled-related protein 4
- 64 STEAP4, STEAP family member 4

65 **Introduction**

66 Infection is associated with the majority of early preterm births, which is a leading cause  
67 of neonatal morbidity and mortality.(1) Infection is often subclinical and thought to  
68 ascend from the lower genital tract allowing microbes to invade the placenta and  
69 amniotic fluid, which can lead to fetal bacteremia and sepsis. The fetal inflammatory  
70 response syndrome describes a condition of severe fetal inflammation that often occurs  
71 with fetal infection. The fetal inflammatory response syndrome is the counterpart to the  
72 adult condition (Systemic Inflammatory Response Syndrome) and is associated with an  
73 increased risk for multi-system fetal organ injury.(2-5) Studies have mainly focused on  
74 the relationship between the fetal inflammatory response syndrome and injury to the  
75 fetal lungs and brain, because they are often imaged and assessed postnatally.  
76 Inflammatory injury to other organs, including the fetal heart, has been hypothesized to  
77 occur, but is more challenging to demonstrate in human neonates. Although many  
78 studies have associated prematurity, low birth weight or fetal growth restriction with  
79 cardiovascular risk factors and heart disease later in life, the impact of perinatal  
80 infection and inflammation on fetal cardiac development is unknown.(6-16)

81

82 Accumulating evidence in humans and preterm sheep models implicates infection and  
83 fetal inflammation in altered fetal cardiac function. Fetal heart rate disturbances (e.g.  
84 absence of variability, arrhythmias, cardiac dysfunction) have been associated with  
85 chorioamnionitis, an inflammation of the placental membranes often caused by  
86 infection.(17-20) In fetuses from pregnancies with preterm premature rupture of  
87 membranes, a condition often complicated by microbial invasion of the amniotic cavity,

88 fetal echocardiography revealed changes in diastolic ventricular function, which may  
89 increase cardiac output.(21) In a similar cohort, strain imaging to evaluate right  
90 ventricular function found evidence for impairment of systolic and diastolic function and,  
91 in cases with funisitis (umbilical cord inflammation), dyskinesia of the right ventricle.(22)  
92 These findings are consistent with observations in preterm sheep models of  
93 intraamniotic infection (*Candida albicans*) or inflammation (lipopolysaccharide; LPS), in  
94 which fetal inflammation was associated with a reduction in mean arterial blood  
95 pressure and oxygen saturation, depressed ventricular contractility, diastolic dysfunction  
96 and a reduction in cardiomyocyte numbers.(23-25) The mechanism linking inflammation  
97 and fetal cardiac injury is unknown and challenging to elucidate in human neonates and  
98 sheep models for ethical reasons and the lack of genomic tools, respectively.

99

100 Our objective was to identify early biological events in the fetal heart occurring after  
101 intrauterine infection and development of fetal inflammatory response syndrome in a  
102 nonhuman primate. We hypothesized that development of the fetal inflammatory  
103 response syndrome is associated with fetal cardiac inflammation and changes in the  
104 gene program responsible for cardiac morphogenesis, analogous to observations that  
105 we have made on the effects of intraamniotic inflammation on fetal lung  
106 development.(26, 27)

107

## 108 **Materials and Methods**

### 109 *Ethics Statement*

110 This study was carried out in strict accordance with the recommendations in the Guide  
111 for the Care and Use of Laboratory Animals of the National Research Council and the  
112 Weatherall report, "The use of non-human primates in research". The protocol was  
113 approved by the Institutional Animal Care Use Committee of the University of Washington  
114 (Permit Number: 4165-01). All surgery was performed under general anesthesia and all  
115 efforts were made to minimize discomfort.

116

### 117 *Animals and Study Groups*

118 Cases meeting criteria for the fetal inflammatory response syndrome were identified  
119 retrospectively in our pregnant nonhuman primate infection program based on an  
120 elevated fetal IL-6 level ( $>11$  pg/ml; N=5) and compared with saline controls (N=5).  
121 Fetal cardiac microarray analyses were performed on animals inoculated with either: 1)  
122  $1-3 \times 10^8$  CFU of a hyperhemolytic and hypervirulent GBS strain (GBS $\Delta covR$ ; N=4) into  
123 the choriodecidual space(28), 2)  $5 \times 10^4$  CFU of *E.coli* RS218 into the amniotic fluid  
124 (prototypic strain causing neonatal meningitis; N=1), or 3) saline into the amniotic fluid  
125 and choriodecidual space (N=5)(29); citations indicate publications that describe the  
126 animal experiments and pregnancy outcomes, but fetal cardiac transcriptomics and IL-  
127  $1\beta$ /IL-6/IL-8 were not previously analyzed or reported. As fetal cardiac tissue from the  
128 above saline controls was not saved to allow for protein (cytokine) analysis, an  
129 additional four saline controls were performed to enable the comparison of cytokines  
130 from fetal cardiac tissues of saline controls with fetal inflammatory response syndrome  
131 cases.

132

133 In our model, pregnant pigtail macaques were time-mated and fetal age determined using  
134 early ultrasound. Temperature in the animal quarters was maintained at 72-82 degrees  
135 Fahrenheit. Animals were fed a commercial monkey chow, supplemented daily with  
136 fruits and vegetables and drinking water was always available. The animal was first  
137 conditioned to a nylon jacket/tether system for several weeks before surgery, which  
138 allows free movement within the cage, but protected the catheters. On day 116-125 of  
139 pregnancy (term=172 days) catheters were surgically implanted via laparotomy into the  
140 maternal femoral artery and vein, amniotic cavity, and choriodecidual interface in the  
141 lower uterine segment (between uterine muscle and fetal membranes, external to the  
142 amniotic cavity). In the *E. coli* case and saline controls, an additional catheter was  
143 implanted into the fetal internal jugular vein. Fetal electrocardiography electrodes and a  
144 maternal temperature probe were also implanted. Post-operative analgesia was  
145 provided by a 25-microgram fentanyl patch applied the day prior to surgery, in addition  
146 to postoperative indomethacin. After 48 hours, the animals appeared to have recovered  
147 from surgery based on a return to baseline for activity, appetite, and bowel function.

148

149 After surgery, the animal was placed in the jacket and tether with the catheters/electrodes  
150 tracked through the tether system. Cefazolin and terbutaline sulfate were administered to  
151 reduce postoperative infection risk and uterine activity. Both cefazolin and terbutaline  
152 were stopped at least 72 hours before experimental start (~13 half-lives for terbutaline,  
153 40 half-lives for cefazolin, >97% of both drugs eliminated), which represented  
154 approximately a 7-10 day period of postoperative terbutaline administration. Cefazolin  
155 (1g) was administered intravenously each day in saline controls to minimize the

156 possibility of a catheter-related infection. Experiments began approximately two weeks  
157 after catheterization surgery to allow recovery (~30-31 weeks human gestation).

158

159 At our center, term gestation in the non-instrumented pigtail macaque population  
160 averages 172 days.

161

162 Intraamniotic pressure was continuously recorded, digitized, and analyzed by previously  
163 described methods. The integrated area under the intrauterine pressure curve was used  
164 as a measure of uterine activity and reported as the hourly contraction area (HCA;  
165 mmHg•sec/hr) over 24 hours. Preterm labor was defined as >10,000 mmHg-sec/hr  
166 associated with a change in cervical effacement or dilation.

167

### 168 *Histology*

169 After cesarean section, fetal necropsy was performed in all animals and the heart was  
170 preserved in RNALater. Histopathologic examination was performed on fetal cardiac  
171 samples. A pathologist (AB) blinded to the case/control status examined H&E-stained,  
172 full-thickness paraffin sections of the fetal hearts to evaluate inflammation, necrosis,  
173 fetal vascular thrombosis, or other histopathological findings.

174

### 175 *Cytokine Analysis*

176 Interleukin-6 (IL-6) was assayed from cardiac tissues (nonhuman primate) and umbilical  
177 cord plasma (nonhuman primate and human) using Luminex multiplex cytokine kits

178 (Millipore, Billerica, MA). Fetal cardiac tissue was not available for protein analysis from  
179 the *E. coli* infection leaving N=4 (GBS $\Delta$ covR) for comparison with controls (N=4).

180

### 181 *Bacterial Quantitation*

182 Amniotic fluid (AF) and maternal blood were sampled frequently *i.e.* before (-24 and -  
183 0.25 hrs) and after bacterial inoculation (+0.75, +6, +12, +24 hrs and then every 12 hrs  
184 until repeat Cesarean section for fetal necropsy). At the time of Cesarean section, we  
185 also collected fetal blood, fetal heart tissues and swabs from the fetal lungs, meninges  
186 and chorioamnion (placental membranes). For enumeration of GBS and *E. coli* from  
187 amniotic fluid or fetal blood (100  $\mu$ L), serial 10-fold dilutions were plated on TSA (GBS)  
188 or Columbia agar with 5% sheep blood (*E. coli*), respectively. Fetal heart tissues from  
189 GBS cases were weighed at necropsy, homogenized in sterile PBS and 10-fold serial  
190 dilutions were plated on TSA and incubated overnight at 37°C, 5% CO<sub>2</sub> and  
191 enumerated the following day as described.(28, 30) Plates were incubated 24 hours at  
192 37°C (GBS) or 72 hours at 35°C (*E. coli*), 5% CO<sub>2</sub> and enumerated. Swabs collected  
193 from tissue were aseptically removed from Port-A-Cul vials and streaked to the same  
194 media as for blood or fluid. No bacteria were recovered from amniotic fluid, fetal blood  
195 or fetal heart tissues from controls.

196

197 For cytokine and prostaglandin (PG) analysis, amniotic fluid and blood samples were  
198 collected in EDTA tubes. Samples were centrifuged for 5 min. at 1200 rpm immediately  
199 after collection and the supernatant was frozen and stored at -80 °C. Prior to freezing,  
200 indomethacin (0.3 mM) was added to the samples saved for cytokine and prostaglandin

201 quantification, respectively. Fetal heart cytokine analysis was performed on tissue  
202 homogenates that were diluted 1:1 in lysis buffer (150 mM NaCl, 15 mM Tris, 1 mM  
203 MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 1% Triton X-100, supplemented with cOmplete™, Mini, EDTA-free  
204 protease inhibitor cocktail (Roche)) and incubated overnight at 4°C. Lysates were then  
205 centrifuged at 4000 rpm for 5 min at 4°C, and supernatants stored at -80°C or used  
206 immediately for analysis. About 100µl of sample was used in Luminex or ELISA assays  
207 as described above.

208

### 209 *RNA Extraction and Microarray Processing*

210 To study genetic pathways in *M. nemestrina*, we used the Affymetrix Cynomolgus Array  
211 (GeneChip Cynomolgus Gene 1.0 ST, Affymetrix, Santa Clara, CA), which allows  
212 interrogation of 40,096 gene-level probe sets based on the *M. fascicularis* genome. *M.*  
213 *nemestrina* and *M. fascicularis* are closely related macaque species and diverged within  
214 the last 5-6 million years (31). RNA extraction was performed using miRNeasy mini kits  
215 (Qiagen, Valencia, CA) following the manufacturer's established protocol for purification  
216 of total RNA from animal tissues. RNA integrity was assessed with an Agilent  
217 Bioanalyzer instrument (Agilent, Santa Clara, CA) and was judged by distinct and sharp  
218 18s and 28s ribosomal RNA peaks that were baseline separated. RNA quantity was  
219 determined by measuring OD<sub>260</sub> with a Thermo Scientific NanoDrop™ 1000  
220 Spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE, USA). The  
221 NanoDrop instrument was also used to determine purity of RNA samples by measuring  
222 OD<sub>260/280</sub> and OD<sub>260/230</sub> ratios. Only samples passing this stringent quality control were  
223 processed further. Processing of the RNA samples was carried out according to the

224 Affymetrix GeneChip Whole Transcript Sense Target labeling protocol. Briefly, double-  
225 stranded cDNA was synthesized with random hexamers tagged with a T7 promoter  
226 sequence. The double-stranded cDNA was subsequently used as a template and  
227 amplified by T7 RNA polymerase producing many copies of antisense cRNA. In the  
228 second cycle of cDNA synthesis, random hexamers were used to prune reverse  
229 transcription of the cRNA from the first cycle to produce single-stranded DNA in the  
230 sense orientation. In order to reproducibly fragment the single-stranded DNA and  
231 improve the robustness of the assay, dUTP was incorporated in the DNA during the  
232 second cycle first-strand reverse transcription reaction. This single-stranded DNA  
233 sample was then treated with a combination of uracil DNA glycosylase (UDG) and  
234 apurinic/apyrimidinic endonuclease 1 (APE 1) that specifically recognizes the unnatural  
235 dUTP residues and breaks the DNA strand. DNA was labeled by terminal  
236 deoxynucleotidyltransferase (TdT) with the Affymetrix® proprietary DNA Labeling  
237 Reagent that is covalently linked to biotin. The biotin labeled DNA fragments were  
238 hybridized to Affymetrix GeneChip Cynomolgus Gene 1.0 ST arrays, washed, and  
239 stained with fluorescent anti streptavidin biotinylated antibody. Following an additional  
240 wash step, the arrays were scanned with an Affymetrix GeneChip® 3000 scanner.  
241 Image generation and feature extraction was performed using Affymetrix GeneChip  
242 Command Console Software.

243

#### 244 *Single gene analysis of microarray data*

245 The microarray data discussed in this publication have been deposited in the National  
246 Center for Biotechnology Information's Gene Expression Omnibus (GEO;

247 <http://www.ncbi.nlm.nih.gov/geo/index.cgi>; GSE98459). Analysis of the microarray data  
248 focused first on differential expression of single genes, which we refer to as the  
249 “ANOVA model.” Raw microarray data were pre-processed and analyzed with various  
250 Bioconductor packages (<http://www.bioconductor.org/>)(32). Several quality control steps  
251 were carried out to ensure data was of high quality: 1) visual inspection of the GCOS  
252 DAT chip images, 2) visual inspection of the chip pseudo-images generated by the  
253 Bioconductor *oligo* package, 3) generation and inspection histograms of raw signal  
254 intensities, and, 4) generation and comparison of the Relative Log Expression and  
255 Normalized Unscaled Standard Errors using the Bioconductor *oligo* package. The data  
256 was normalized with the Bioconductor *oligo* package(33) using Robust Multiarray  
257 Averaging (RMA).(34) We did not filter out any probesets prior to analysis. From the  
258 normalized data, genes with significant evidence for differential expression were  
259 identified using the *limma* package in Bioconductor.(35) Changes in expression were  
260 inferred using a weighted t-test in conjunction with an empirical Bayes method to  
261 moderate the standard errors of the estimated log-fold changes. Array weights were  
262 estimated by computing the relative variability of each array, and then using the inverse  
263 of the variance to weight each array.(36) This allows smooth adjustment for array  
264 quality without having to exclude samples. We selected genes based on an unadjusted  
265 p-value < 0.05 and a 1.5-fold difference between groups.

266

267 We also fit a conventional linear model using IL-6 concentrations (log base 2) as a  
268 marker for infection severity, which we refer to as the “IL-6 model.” In this model, we  
269 excluded two saline controls for which we did not have an IL-6 level. We selected genes

270 with an unadjusted p-value  $< 0.05$  and an absolute slope  $> 0.07$ . This slope can be  
271 interpreted as a 5% change in expression for every doubling of IL-6 concentration.  
272 Given that the range of observed IL-6 concentrations is  $> 14$  logs (e.g., more than 14  
273 doublings in concentration), this represents an approximate 1.6-fold change in  
274 expression, at minimum, over the entire range of observed IL-6 concentrations.

275

### 276 *Gene Set Analysis*

277 Next, the data was analyzed using gene set tests to investigate categories of genes,  
278 using the *romer* function from the Bioconductor *limma* package. The *romer* function is  
279 intended to perform a competitive test against a battery of gene sets, assessing the  
280 statistical significance of pre-defined gene sets/pathways as a whole rather than of  
281 single genes. This method facilitates identification of modest but concordant changes in  
282 expression of a set of genes that may be missed by single gene analysis. Gene set  
283 testing considers all the genes in the experiment and allows for the identification of gene  
284 sets that are more highly ranked, as a set, than would be expected under the null  
285 hypothesis. The p-values are based on random rotations of the residuals (9,999 random  
286 rotations), which is similar to conventional permutation tests, but permits unlimited  
287 numbers of permutations to be tested. In addition, the *romer* function works with any  
288 linear model, not just ANOVA; we used the linear regression function against IL-6  
289 concentration for gene set testing and Ingenuity Pathway Analysis (see below). In the  
290 IL-6 model, we excluded two controls for which fetal plasma was not obtained and the  
291 IL-6 level was unknown (Saline 1 and 3, Table 1). We used the Gene Ontology and

292 Hallmark gene set collections from the Broad Institute  
293 (<http://software.broadinstitute.org/gsea/msigdb>)(37).

294

295 To determine overlap in gene expression between our data and the fetal blood  
296 transcriptome associated with the fetal inflammatory response syndrome(38), we  
297 created a self-contained gene set using 36 of the 41 validated genes from the fetal  
298 blood transcriptome study that could be mapped to our nonhuman primate array. Using  
299 the roast function from the Bioconductor *limma* package, we tested if the 36 genes in  
300 the set were, on average, differentially expressed.

301

### 302 *Ingenuity Pathway Analysis*

303 The Core analysis feature of the Ingenuity Pathway Analysis software (Ingenuity  
304 Systems, [www.ingenuity.com](http://www.ingenuity.com)) was used to discover pathways and transcriptional  
305 networks in the gene expression microarray data from the IL-6 model. The Functional  
306 Analysis feature identified the biological functions and/or diseases that were most  
307 significant to the data set. Given that the range of observed IL-6 concentrations is > 14  
308 logs, this represents an approximate 1.6-fold change in expression, at minimum, over  
309 the entire range of observed IL-6 concentrations. Ingenuity Pathway Analysis uses a  
310 right-tailed Fisher's exact test to calculate a p-value determining the probability that  
311 each biological function and/or disease assigned to that data set is due to chance alone.  
312 Molecules are represented as nodes, and the biological relationship between two nodes  
313 is represented as an edge (line). All edges are supported by at least one reference from  
314 the literature, from a textbook, or from canonical information stored in the Ingenuity

315 Knowledge Base. Human, mouse, and rat orthologs of a gene are stored as separate  
316 objects in the Ingenuity Knowledge Base, but are represented as a single node in the  
317 network. The intensity of the node color indicates the degree of up- (red) or down-  
318 (green) regulation. Nodes are displayed using various shapes that represent the  
319 functional class of the gene product. Edges are displayed with labels that describe the  
320 nature of the relationship between the nodes (see figure legends for details). Ingenuity  
321 Pathway Analysis also allows prediction of the activation or inhibition of transcription  
322 factors involved in the gene expression patterns seen in our study.

323

#### 324 *Validation of cDNA microarray by qRT-PCR*

325 We used qRT-PCR to validate expression changes of genes of interest that had been  
326 identified by microarray analysis. Briefly, reverse transcription was performed according  
327 to the manufacturer's established protocol using total RNA and the SuperScript® III  
328 First-Strand Synthesis System (Invitrogen, Carlsbad, CA.). For gene expression  
329 measurements, 2  $\mu$ L of cDNA was included in a PCR (12  $\mu$ L final volume) that also  
330 consisted of the ABI TaqMan® Gene Expression Assays mix and the TaqMan Gene  
331 Expression Master Mix according to the manufacturer's protocol (Applied Biosystems,  
332 ThermoFisher Scientific, Foster City, CA). Amplification and detection of PCR amplicons  
333 were performed with the ABI PRISM 7900 system (Applied Biosystems Inc., Foster City,  
334 CA) with the following PCR profile: 1 cycle of 95°C for 10 min, 40 cycles of 95°C for 30  
335 s, and 60°C for 1 min. GAPDH amplification plots derived from serial dilutions of an  
336 established reference sample were used to create a linear regression formula in order  
337 to calculate expression levels, and  $\beta$ -actin gene expression levels were utilized as an

338 internal control to normalize the data.

339

#### 340 *Statistical Analysis*

341 Statistical analyses related to the transcriptomics data are detailed above in their  
342 respective sections. We used a t-test for the analysis of Real-Time PCR data. A Mann-  
343 Whitney test was also performed to test comparisons between cases and controls for  
344 cytokine quantities.

345

### 346 **Results**

#### 347 *Preterm Labor and Fetal Cardiac Infection in a Nonhuman Primate Model of Severe* 348 *Fetal Inflammation*

349 To understand biological events induced by inflammation in the fetal heart, we used a  
350 unique, chronically catheterized, nonhuman primate model (pigtail macaque, *Macaca*  
351 *nemestrina*) of infection-induced preterm labor. From our pregnancy infection program,  
352 we retrospectively identified five cases with severe fetal inflammation consistent with the  
353 fetal inflammatory response syndrome (N=4 GBS and N=1 *E. coli*; fetal plasma IL-6:  
354 157 – 29,294 pg/mL) and three saline controls (Table 1). In all fetal inflammatory  
355 response syndrome cases, there was acute and severe chorioamnionitis. The *E. coli*  
356 case was delivered in preterm labor 2.5 days after inoculation. Three of the four GBS  
357 cases were delivered at the time of preterm labor (0.3, 1.0 and 2.0 days after  
358 inoculation). One of the four GBS cases was delivered 2.0 days after inoculation without  
359 preterm labor in an effort to avoid stillbirth due to a marked change in color and turbidity  
360 of the amniotic fluid indicating heavy bacterial growth.(28) All controls were delivered in

361 the absence of preterm labor at 7 days post-inoculation to obtain gestational age  
362 matched tissues.(26)

363

364 In four of five cases, the fetal inflammatory response syndrome accompanied a  
365 disseminated bacterial infection into the fetal blood and/or organs. Bacteria were  
366 cultured and quantified from fetal heart tissues in all four fetal inflammatory response  
367 syndrome cases induced by GBS inoculation (Fig. 1A). Although fetal heart tissue was  
368 not specifically tested for bacteria from the *E. coli* case,  $10^7$  CFU were recovered from  
369 both fetal lungs and blood indicating a severe fetal infection. In fetal cardiac tissues,  
370 levels of IL-6 and IL-8 were significantly higher in fetal inflammatory response syndrome  
371 cases than in controls (Fig. 1A,  $p=0.03$ ). IL- $1\beta$  and TNF- $\alpha$  levels were not significantly  
372 different, but approached statistical significance for TNF- $\alpha$  (Fig. 1A,  $p=0.06$ ). Blinded  
373 evaluation of fetal cardiac tissues did not reveal significant changes in gross pathology  
374 (Table S1). In the case with the highest fetal plasma IL-6 levels (induced by *E. coli*),  
375 there were areas with cytoplasmic pallor, but otherwise neutrophilic infiltrates or  
376 significant inflammation was not observed (Fig. 1B-C).

377

#### 378 *Fetal Cardiac Single Gene Analysis and Quantitative RT-PCR (qRT-PCR) Validation*

379 To identify changes in the fetal cardiac gene program, we performed a single gene  
380 analysis of microarray results by two methods: 1) ANOVA (case-control comparison)  
381 and 2) linear regression correlating fetal plasma IL-6 to gene expression regardless of  
382 experimental group (IL-6 model). In the ANOVA analysis, 609 probe sets were  
383 differentially expressed  $>1.5$  fold ( $p<0.05$ ) between fetal inflammatory response

384 syndrome cases and controls. According to the IL-6 model, 1162 probe sets were  
385 significantly differentially expressed ( $p < 0.05$ ). Genes significantly downregulated in both  
386 types of analyses included *SFRP4*, *NPPA*, *PLA2G7*, *GRIA3*, *MTHFR*, *EPHA4*,  
387 *ANGPTL7* (ANOVA:  $\log_2$  fold changes range from -2.7 to -1.3,  $p < 0.05$ ; IL-6 model:  
388  $p < 0.02$ ; Table 2, Fig. S1). In both analyses, genes significantly upregulated included  
389 *S100A8*, *FAM69C*, *PLA2G2*, *CFTR*, *STEAP4*, and *IRX4* (case-control:  $\log_2$  fold  
390 changes range from 1.2 to 2.6,  $p < 0.05$ ; IL-6 model:  $p < 0.02$ ; Table 2). Of the 609  
391 significant genes from the ANOVA analysis, 452 were also significant in the IL-6 model  
392 (with consistent direction of change). The probability that this would occur by chance,  
393 under a hypergeometric null distribution, corresponds to a p-value less than  $1 \times 10^{-16}$ .  
394 To validate our microarray data, we performed quantitative RT-PCR on 10 genes of  
395 interest. Nine of ten genes were significantly differentially expressed between fetal  
396 inflammatory response syndrome cases and controls: *SFRP4*, *NPPA*, *MAL2*,  
397 *ANGPTL7*, *FAM69C*, *ACE2*, *CFTR*, *STEAP4* and *IRX4* ( $p < 0.05$ , Fig. 1D).

398

### 399 *Gene Set and Ingenuity Pathway Analysis*

400 To explore relationships among differentially expressed genes, we identified gene sets  
401 and pathways with concordant changes in expression by performing Gene Set Analysis  
402 for data obtained with the IL-6 model. Multiple gene sets related to morphogenesis were  
403 significantly downregulated with increasing IL-6 level including cellular morphogenesis  
404 during differentiation ( $p = 0.008$ , Fig. 1E), neuron differentiation ( $p = 0.008$ ), axonogenesis  
405 ( $p = 0.008$ ), and regulation of DNA replication ( $p = 0.03$ ; Table 3). To place the findings of  
406 disruptions in gene networks for cellular morphogenesis within a visual construct, the

407 Ingenuity Pathway Core Analysis feature was used to map functional networks of  
408 relevant genes. We also used the data obtained with the IL-6 model as input for the  
409 Ingenuity Pathway Analysis. Multiple pathways differentially regulated within the  
410 Ingenuity Pathway Analysis “Diseases and Biological Functions” category were related  
411 to cardiac morphogenesis and vasculogenesis including morphology of the  
412 cardiovascular system (Fig. 2), cellular movement and migration of cells, growth of  
413 smooth muscle, morphology of vessel, growth of muscle tissue, and vasculogenesis  
414 and migration of endothelial cells (Table 3; p value range:  $4 \times 10^{-8} - 7 \times 10^{-21}$ ). Ingenuity  
415 Pathway Analysis also has the capability to predict activation states of transcriptional  
416 regulators based on the activation or suppression of downstream genes. The top  
417 transcription factors predicted to be associated with changes in gene expression were  
418 *TNF* (tumor necrosis factor), *TGFB1* (transforming growth factor, beta 1), and *IL-1B* (IL-  
419 1 beta; p value range:  $2 \times 10^{-10} - 2 \times 10^{-14}$ ). These data suggest that multiple pathways  
420 related to fetal cardiac morphogenesis may be impacted by the development of the fetal  
421 inflammatory response syndrome and/or fetal bacteremia.

422

423 The human blood transcriptome associated with the fetal inflammatory response  
424 syndrome has been described by Madsen-Bouterse et al(38) and provides an  
425 opportunity to directly compare gene expression in different fetal compartments  
426 between human and nonhuman primate fetuses. Thirty-six of the 41 validated genes  
427 reported by Madsen-Bouterse et al could be mapped to our nonhuman primate array. A  
428 self-contained gene set test was then used to determine if any of the 36 genes identified  
429 in the human fetal blood transcriptome were differentially expressed in the nonhuman

430 primate fetal cardiac tissues. We observed that 33% of these genes were upregulated in  
431 our ANOVA model ( $p=0.04$ ) and 44% were upregulated in the IL-6 model ( $p=0.008$ ).  
432 Overall, there is significant overlap between the transcriptomes derived from human  
433 blood and nonhuman primate cardiac tissues in the setting of severe fetal inflammation.

434

## 435 **Comment**

### 436 **Principal Findings of the Study**

437 Our study is the first to demonstrate that fetal infection and inflammation was associated  
438 with changes in the cardiac developmental gene program involving a disruption in gene  
439 networks for morphogenesis and vasculogenesis in a nonhuman primate model of  
440 infection-associated preterm labor (conceptual model, Fig. 3). Principal findings of the  
441 study are: 1) pro-inflammatory cytokines (IL-6, IL-8) are elevated in the fetal  
442 myocardium without significant evidence of histopathologic inflammation during an early  
443 stage of the infection and inflammatory response; 2) a consistent set of genes is  
444 differentially regulated with fetal infection and fetal inflammatory response syndrome by  
445 either case-control analysis or correlation with IL-6 levels (e.g. *NPPA*); and 3) genes  
446 differentially expressed in the nonhuman primate fetal heart are involved in cardiac  
447 morphogenesis and vasculogenesis.

448

### 449 **Results in the Context of What is Known**

450 Strong epidemiological evidence implicates a fetal origin for adult heart disease and  
451 related risk factors.(6-16) Our results of perturbations in the fetal cardiac developmental  
452 gene program in cases with preterm labor, infection and the fetal inflammatory response

453 syndrome provide a link between preterm birth and adult cardiovascular disease. During  
454 pregnancy, diastolic dysfunction has been reported in human fetuses after preterm  
455 premature rupture of membranes, which is a condition typically complicated by an  
456 intraamniotic infection.(21) In preterm sheep models, amniotic fluid inoculation of either  
457 lipopolysaccharide or *Candida albicans* was associated with fetal cardiac dysfunction  
458 (diastolic dysfunction, reductions in ventricular contractility and cardiomyocyte density,  
459 hypertrophy of mature cardiomyocytes).(23, 24) Our work extends these observations in  
460 pregnancy by associating intraamniotic infection with the production of pro-inflammatory  
461 cytokine mediators in the fetal heart, severe fetal inflammation and perturbations in the  
462 preterm cardiac developmental gene program.

463

464 The long-term effects of infectious and/or inflammatory injury on the developing fetal  
465 heart are unknown, but the idea that adverse events in fetal life might predispose  
466 towards adult disease is consistent with a body of literature often referred to as the  
467 “Barker hypothesis”.(39) David Barker, a British epidemiologist, proposed a causal  
468 association between intrauterine growth retardation, low birth weight and preterm birth  
469 with the development of cardiovascular disease, hypertension and diabetes in middle  
470 age based on a cohort in the United Kingdom.(40-42) Subsequent epidemiological  
471 studies supported a relationship between preterm birth and increased blood  
472 pressure,(7, 43-52) a major risk factor for coronary heart disease and stroke. A recent  
473 large epidemiologic study using a Swedish birth cohort found a 17-fold increased risk of  
474 heart failure in the first year of life after preterm birth (95% CI: 7.96 - 36.3), which  
475 provides even stronger evidence for an ominous effect of preterm birth on cardiac

476 development.(16) A series of physiologic and imaging studies in 102 adults born  
477 preterm revealed significant changes in their myocardial structure and function  
478 compared to controls.(53-55) Experiments in animal models and observations from  
479 human neonates born preterm also demonstrate altered cardiac structure  
480 (cardiomyocyte and cardiac hypertrophy) following preterm birth(56, 57) or neonatal  
481 exposure to a hyperoxic environment.(58, 59) Our data suggests that preterm birth  
482 complicated by severe fetal inflammation is more likely to be associated with a long-  
483 term risk of heart disease for surviving neonates.

484

485 **Pro-inflammatory response in the fetal heart without evidence of histopathologic**  
486 **inflammation in the acute stages of fetal infection and the fetal inflammatory**  
487 **response syndrome**

488 Neutrophils can injure cardiomyocytes through respiratory burst and oxidative injury(60),  
489 but neutrophilic infiltration was minimal or absent in the heart tissues in our study  
490 suggesting that either bacteria or cytokines played a greater role in perturbing fetal  
491 cardiac developmental gene networks. Although it is well established that bacterial cell  
492 wall components (e.g. lipopolysaccharide) and inflammatory cytokines can induce direct  
493 cardiodepressive effects on adults with sepsis, evidence is only beginning to  
494 accumulate that the fetal heart is similarly vulnerable to infectious and inflammatory  
495 injury.(61-64) GBS does not produce LPS, but the GBS hemolytic toxin overexpressed  
496 by the strain in this study [GBS $\Delta$ covR,(28)] has been shown to injure cardiomyocytes *in*  
497 *vitro* and induce a rapid loss of function and viability.(65) Polymicrobial infections are  
498 common in cases of early preterm birth and there is evidence that cell wall fragments

499 from gram-positive and gram-negative bacteria (e.g. peptidoglycan and  
500 lipopolysaccharide) can also synergize to induce release of cytokines and injure  
501 organs.(66) The latency between bacterial inoculation and delivery was fairly short in  
502 our study (maximum 2.5 days); therefore, fetuses exposed to infection for a longer time  
503 *in utero* may have a greater degree of leukocytic infiltration in their cardiac tissues, more  
504 complex mechanisms of cardiac injury and changes in the expression of their  
505 developmental gene networks.

506

### 507 **Differential gene expression in the fetal heart with infection and the fetal** 508 **inflammatory response syndrome**

509 A consistent set of genes was differentially regulated in association with the diagnosis of  
510 the fetal inflammatory response syndrome or rising IL-6 levels and included *SFRP4*,  
511 *NPPA*, *MAL2*, *ANGPTL7*, *FAM69C*, *ACE2*, *CFTR*, *STEAP4* and *IRX4*. *MYH6* was also  
512 significantly downregulated when correlated with IL-6 levels. Of these genes, *NPPA* and  
513 *MYH6* have known roles in cardiac morphogenesis and gene mutations have been  
514 linked to development of arrhythmias and cardiomyopathy in the adult.(67, 68) *NPPA*  
515 encodes atrial natriuretic peptide (ANP), which is an early and specific marker for  
516 functional myocardium of the embryonic heart; expression of *NPPA* is essential for  
517 formation and expansion of the cardiac chambers.(69, 70) During fetal life, there is a  
518 dynamic and patterned expression of *NPPA* throughout the heart and ANP suppresses  
519 proliferation of cardiomyocytes near term in response to growth-promoting stimuli.(71,  
520 72) A premature downregulation of *NPPA* may restrict growth potential of the fetal heart.  
521 *ACE2* expression is thought to have a protective role for the heart in pathologic settings

522 and downregulation of *ACE2* may also be harmful for development.(73) Several single  
523 genes with altered expression in our study have known functions in cardiac  
524 development or are implicated in heart disease or cardiac injury repair.

525

### 526 **Downregulation of cardiac morphogenesis and vasculogenesis gene networks**

527 Multiple gene sets, biological pathways and transcription factors related to  
528 morphogenesis and vasculogenesis (cellular movement, TGF- $\beta$  signaling, epithelial-  
529 mesenchymal transition, cellular morphogenesis during differentiation, morphology of  
530 the cardiovascular system, and morphology of blood vessel) were disrupted in the  
531 context of fetal infection and inflammation. By Gene Set Analysis and Ingenuity  
532 Pathway Analysis, multiple pathways related to cardiac morphogenesis and  
533 vasculogenesis were differentially regulated in cases with fetal infection and the fetal  
534 inflammatory response syndrome suggesting multiple mechanisms and pathways for  
535 injury. Although the atria and ventricles have formed by week 10, the fetal heart  
536 continues to develop and grow until birth(71); disruptions in cardiomyocyte growth  
537 patterns imposed by an infection in the late second or third trimester may restrict growth  
538 potential and lead to compensatory changes such as cardiomyocyte hypertrophy.  
539 Downregulation of vasculogenesis during fetal life is particularly important as coronary  
540 vessels continue to develop *de novo* in postnatal life, which is necessary to augment  
541 growth of the coronary vasculature.(74) There was also significant overlap between the  
542 our data in nonhuman primate cardiac tissues and the human blood transcriptome from  
543 fetuses with the fetal inflammatory response syndrome (38); as leukocytes in fetal  
544 cardiac tissues were minimal or absent, we conclude that an overlap in gene expression

545 between our studies reflects a shared biological response across preterm  
546 cardiomyocytes and leukocytes to systemic infection and inflammation. Notably, a  
547 similar transcriptomic profile of downregulation in morphogenesis pathways was  
548 observed in our prior studies of gene expression in the nonhuman primate fetal lung in  
549 response to intraamniotic inflammation with a lesser degree of fetal inflammation.(26,  
550 75)

551

## 552 **Clinical Implications**

553 The question of whether infection and fetal inflammation disrupts fetal heart  
554 development is of critical importance, because an intraamniotic infection occurs in  
555 approximately half of pregnancies with preterm premature rupture of membranes  
556 (pPROM).(76-78) Cardiac dysfunction has also been described in fetuses with  
557 pPROM.(21, 22) Further, an elevated plasma IL-6 level, diagnostic of the fetal  
558 inflammatory response syndrome, is associated with neonatal hypotension, which can  
559 be the result of low cardiac output and altered myocardial contractility.(79, 80) Our study  
560 provides critical evidence that infection and severe inflammation in utero disrupts the  
561 developmental genetic program of the fetal heart *before* birth. The extent to which an  
562 interrupted genetic program for organ development can be restored post-birth is  
563 unknown, but a number of interventions in the neonatal intensive care unit are also  
564 associated with an inflammatory stress (e.g. mechanical ventilation, supplemental  
565 oxygen).(81-83) Overall, this study suggests that in addition to risks of neonatal  
566 mortality, neurologic and pulmonary morbidity, some preterm infants have altered  
567 cardiac development beginning with inflammatory injury *in utero*.

568

569 **Research Implications**

570 A nonhuman primate model of infection-associated preterm labor affords a rare  
571 opportunity to investigate the fetal origins of abnormal cardiac development that can  
572 lead to adult heart disease. Many important questions remain as to how this risk may be  
573 amplified by common neonatal interventions and whether anti-inflammatory therapeutics  
574 administered in utero or postnatally might lessen this risk. In our study, fetuses were  
575 exposed to intraamniotic infection and had severe systemic inflammation, but whether a  
576 disruption of cardiac development occurs in preterm labor cases with a lesser degree of  
577 fetal inflammation is unknown. Our experiments were not originally designed to  
578 investigate heart function and additional work is needed to correlate changes in fetal  
579 cardiac transcriptomics with heart function and anatomical changes in the myocardium  
580 and vascularity. Whether therapeutic inhibition of inflammation in preterm infants may  
581 reduce the long-term risks of heart disease is unknown, but a critical question for  
582 prevention of life course morbidity. Therapeutics targeting inflammation in pre-clinical  
583 studies of preterm labor should be studied for their effect on the transcriptomic profile of  
584 fetal organs to determine if disruptions in developmental gene networks can be  
585 ameliorated in the fetal heart.

586

587 **Strengths and Weaknesses**

588 The strength of our study is in the novel finding of a disruption in morphogenesis gene  
589 networks in the fetal heart following intraamniotic infection and development of the fetal  
590 inflammatory response syndrome. Furthermore, the nonhuman primate shares many  
591 key features with human pregnancy (e.g. placentation, hormonal onset of labor), which

592 differ in other animal models of preterm birth (e.g. murine, sheep). The main study  
593 limitation is the modest sample size, which is necessary for ethical reasons,  
594 conservation of nonhuman primates and expense of the studies. Notably, our  
595 nonhuman primate model is consistent with the effects of a disseminated bacterial  
596 infection and severe systemic fetal inflammation; whether or not our results are  
597 applicable to inflammation in the absence of bacteremia or a lesser magnitude of the  
598 fetal inflammatory response syndrome is unknown.(84) Another important feature of our  
599 model is the short time course from bacterial inoculation to delivery and fetal necropsy  
600 (typically 2 days); histopathologic inflammation or overt signs of cardiac injury in the  
601 fetal heart may not have had sufficient time to develop. Our results are best applied to a  
602 severe infectious/inflammatory insult to the fetus in the late second or early third  
603 trimester (~28 weeks) as the influence of infection on fetal development is likely  
604 gestational age dependent.(85) The combination of cases using two different microbes  
605 (GBS and *E. coli*) as inciting agents of the fetal inflammatory response syndrome was  
606 necessary to establish sufficient power for the analysis; however, this mix of microbes is  
607 also typical of human case series of preterm labor and the fetal inflammatory response  
608 syndrome. Finally, we acknowledge that the effect of systemic fetal inflammation and  
609 preterm birth on gene expression in the fetal heart may involve multiple factors beyond  
610 simply the infectious/inflammatory component that may also function to increase the risk  
611 of cardiovascular disease in adulthood such as a reduction in fetal systolic blood  
612 pressure due to sepsis(86); oxidative stress(87); nutritional support such as lipid  
613 infusions(88); and formula feeding.(89)

614

615 **Conclusion**

616 Our study offers new insight into the effect of fetal infection and inflammation on the  
617 dynamic regulation of genetic pathways programming fetal cardiac morphogenesis and  
618 vasculogenesis. This data provides a framework by which to understand how early  
619 biological changes impart a risk for cardiovascular disease later in life. Rapid changes in  
620 the fetal cardiac genetic program after bacterial inoculation suggest that inflammatory  
621 injury to the fetal heart occurs quickly after a virulent bacterial strain invades the  
622 amniotic cavity. An important question is whether an intervention combining antibiotic  
623 and anti-inflammatory therapeutics can ameliorate fetal organ inflammatory injury and  
624 restore a normal developmental genetic program in the fetal heart.

625 **Acknowledgements**

626 We would like to acknowledge Dr. Chuck Murry for his assistance with interpretation of  
627 the histopathology. We thank Mrs. Jan Hamanishi for technical assistance with graphic  
628 design and Ms. Geena Gallardo for administrative assistance. We also thank Dr. Marie-  
629 Terese Little for technical editing.

630

631 **Data Availability**

632 The microarray data discussed in this publication have been deposited in the National  
633 Center for Biotechnology Information's Gene Expression Omnibus (GEO;  
634 <http://www.ncbi.nlm.nih.gov/geo/index.cgi>; GSE98459) and will be made publicly  
635 available upon manuscript acceptance.

636

637

## References

1. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. *Science (New York, NY)*. 2014;345(6198):760-5.
2. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al. The fetal inflammatory response syndrome. *Clin Obstet Gynecol*. 2007;50(3):652-83.
3. Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edwin SS, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. *Am J Obstet Gynecol*. 1998;179(1):186-93.
4. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am J Obstet Gynecol*. 1998;179(1):194-202.
5. Robertson CM, Coopersmith CM. The systemic inflammatory response syndrome. *Microbes Infect*. 2006;8(5):1382-9.
6. Mercurio G, Bassareo PP, Flore G, Fanos V, Dentamaro I, Scicchitano P, et al. Prematurity and low weight at birth as new conditions predisposing to an increased cardiovascular risk. *Eur J Prev Cardiol*. 2013;20(2):357-67.
7. Dalziel SR, Parag V, Rodgers A, Harding JE. Cardiovascular risk factors at age 30 following pre-term birth. *Int J Epidemiol*. 2007;36(4):907-15.
8. Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ. Early growth and coronary heart disease in later life: longitudinal study. *BMJ*. 2001;322(7292):949-53.
9. Leeson CP, Kattenhorn M, Morley R, Lucas A, Deanfield JE. Impact of low birth weight and cardiovascular risk factors on endothelial function in early adult life. *Circulation*. 2001;103(9):1264-8.
10. Barker DJ. Fetal origins of coronary heart disease. *BMJ*. 1995;311(6998):171-4.
11. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz GA, et al. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. *BMJ*. 1997;315(7105):396-400.
12. Gamborg M, Byberg L, Rasmussen F, Andersen PK, Baker JL, Bengtsson C, et al. Birth weight and systolic blood pressure in adolescence and adulthood: meta-regression analysis of sex- and age-specific results from 20 Nordic studies. *Am J Epidemiol*. 2007;166(6):634-45.
13. Willemsen RH, de Kort SW, van der Kaay DC, Hokken-Koelega AC. Independent effects of prematurity on metabolic and cardiovascular risk factors in short small-for-gestational-age children. *J Clin Endocrinol Metab*. 2008;93(2):452-8.
14. Crispi F, Bijnen B, Figueras F, Bartrons J, Eixarch E, Le Noble F, et al. Fetal growth restriction results in remodeled and less efficient hearts in children. *Circulation*. 2010;121(22):2427-36.
15. Bassareo PP, Fanos V, Crisafulli A, Mura R, Mercurio G. Cardiovascular phenotype in extremely low birth weight infants: long-term consequences. *J Matern Fetal Neonatal Med*. 2011;24 Suppl 2:3-5.
16. Carr H, Cnattingius S, Granath F, Ludvigsson JF, Edstedt Bonamy AK. Preterm Birth and Risk of Heart Failure Up to Early Adulthood. *J Am Coll Cardiol*. 2017;69(21):2634-42.
17. Duff P, Sanders R, Gibbs RS. The course of labor in term patients with chorioamnionitis. *Am J Obstet Gynecol*. 1983;147(4):391-5.

18. Hauth JC, Gilstrap LC, 3rd, Hankins GD, Connor KD. Term maternal and neonatal complications of acute chorioamnionitis. *Obstet Gynecol.* 1985;66(1):59-62.
19. Wendel PJ, Cox SM, Roberts SW, Dax J, Gilstrap LC. Chorioamnionitis: association of nonreassuring fetal heart-rate patterns and interval from diagnosis to delivery on neonatal outcome. *Infectious diseases in obstetrics and gynecology.* 1994;2(4):162-6.
20. Yanowitz TD, Jordan JA, Gilmour CH, Towbin R, Bowen A, Roberts JM, et al. Hemodynamic disturbances in premature infants born after chorioamnionitis: association with cord blood cytokine concentrations. *Pediatr Res.* 2002;51(3):310-6.
21. Romero R, Espinoza J, Goncalves LF, Gomez R, Medina L, Silva M, et al. Fetal cardiac dysfunction in preterm premature rupture of membranes. *J Matern Fetal Neonatal Med.* 2004;16(3):146-57.
22. Di Naro E, Cromi A, Ghezzi F, Giocolano A, Caringella A, Loverro G. Myocardial dysfunction in fetuses exposed to intraamniotic infection: new insights from tissue Doppler and strain imaging. *Am J Obstet Gynecol.* 2010;203(5):459 e1-7.
23. Tare M, Bensley JG, Moss TJ, Lingwood BE, Kim MY, Barton SK, et al. Exposure to intrauterine inflammation leads to impaired function and altered structure in the preterm heart of fetal sheep. *Clin Sci (Lond).* 2014;127(9):559-69.
24. Stock SJ, Patey O, Thilaganathan B, White S, Furfaro LL, Payne MS, et al. Intrauterine *Candida albicans* Infection Causes Systemic Fetal Candidiasis With Progressive Cardiac Dysfunction in a Sheep Model of Early Pregnancy. *Reproductive sciences (Thousand Oaks, Calif).* 2016.
25. Seehase M, Gantert M, Ladenburger A, Garnier Y, Kunzmann S, Thomas W, et al. Myocardial response in preterm fetal sheep exposed to systemic endotoxaemia. *Pediatr Res.* 2011;70(3):242-6.
26. Adams Waldorf KM, Gravett MG, McAdams RM, Paoletta LJ, Gough GM, Carl DJ, et al. Choriodecidual Group B Streptococcal Inoculation Induces Fetal Lung Injury without Intra-Amniotic Infection and Preterm Labor in *Macaca nemestrina*. *PloS one.* 2011;6(12):e28972.
27. McAdams RM, Bierle CJ, Boldenow E, Weed S, Tsai J, Beyer RP, et al. Choriodecidual Group B Streptococcal Infection Induces miR-155-5p in the Fetal Lung in *Macaca nemestrina*. *Infect Immun.* 2015;83(10):3909-17.
28. Boldenow E, Gendrin C, Ngo L, Bierle C, Vornhagen J, Coleman M, et al. Group B Streptococcus Circumvents Neutrophils and Neutrophil Extracellular Traps during Amniotic Cavity Invasion and Preterm Labor. *Sci Immunol.* 2016;1(4).
29. Waldorf KM, Gravett MG, McAdams RM, Paoletta LJ, Gough GM, Carl DJ, et al. Choriodecidual group B streptococcal inoculation induces fetal lung injury without intra-amniotic infection and preterm labor in *Macaca nemestrina*. *PloS one.* 2011;6(12):e28972.
30. Gendrin C, Vornhagen J, Ngo L, Whidbey C, Boldenow E, Santana-Ufret V, et al. Mast cell degranulation by a hemolytic lipid toxin decreases GBS colonization and infection. *Sci Adv.* 2015;1(6):e1400225.
31. Disotell TR, Tosi AJ. The monkey's perspective. *Genome biology.* 2007;8(9):226.
32. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome biology.* 2004;5(10):R80.

33. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. *Bioinformatics*. 2010;26(19):2363-7.
34. Zhijin W, Irizarry RA, Gentleman R, Murillo FM, Spencer F. A model based background adjustment for oligonucleotide expression arrays. *J Am Stat Assoc*. 2004;99(468):909-17.
35. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol*. 2004;3:Article3.
36. Ritchie ME, Diyagama D, Neilson J, van Laar R, Dobrovic A, Holloway A, et al. Empirical array quality weights in the analysis of microarray data. *BMC Bioinformatics*. 2006;7:261.
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005;102(43):15545-50.
38. Madsen-Bouterse SA, Romero R, Tarca AL, Kusanovic JP, Espinoza J, Kim CJ, et al. The transcriptome of the fetal inflammatory response syndrome. *American journal of reproductive immunology (New York, NY : 1989)*. 2010;63(1):73-92.
39. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. *N Engl J Med*. 2008;359(1):61-73.
40. Barker DJ. The fetal and infant origins of adult disease. *BMJ*. 1990;301(6761):1111.
41. Barker DJ. Fetal nutrition and cardiovascular disease in later life. *Br Med Bull*. 1997;53(1):96-108.
42. Barker DJ, Martyn CN. The maternal and fetal origins of cardiovascular disease. *J Epidemiol Community Health*. 1992;46(1):8-11.
43. Siewert-Delle A, Ljungman S. The impact of birth weight and gestational age on blood pressure in adult life: a population-based study of 49-year-old men. *Am J Hypertens*. 1998;11(8 Pt 1):946-53.
44. Bensley JG, De Matteo R, Harding R, Black MJ. The effects of preterm birth and its antecedents on the cardiovascular system. *Acta obstetrica et gynecologica Scandinavica*. 2016;95(6):652-63.
45. Bonamy AK, Martin H, Jorreskog G, Norman M. Lower skin capillary density, normal endothelial function and higher blood pressure in children born preterm. *J Intern Med*. 2007;262(6):635-42.
46. Bonamy AK, Bendito A, Martin H, Andolf E, Sedin G, Norman M. Preterm birth contributes to increased vascular resistance and higher blood pressure in adolescent girls. *Pediatr Res*. 2005;58(5):845-9.
47. Rossi P, Tauzin L, Marchand E, Boussuges A, Gaudart J, Frances Y. Respective roles of preterm birth and fetal growth restriction in blood pressure and arterial stiffness in adolescence. *J Adolesc Health*. 2011;48(5):520-2.
48. Johansson S, Iliadou A, Bergvall N, Tuvemo T, Norman M, Cnattingius S. Risk of high blood pressure among young men increases with the degree of immaturity at birth. *Circulation*. 2005;112(22):3430-6.
49. Leon DA, Johansson M, Rasmussen F. Gestational age and growth rate of fetal mass are inversely associated with systolic blood pressure in young adults: an epidemiologic study of 165,136 Swedish men aged 18 years. *Am J Epidemiol*. 2000;152(7):597-604.

50. de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. *Hypertension*. 2012;59(2):226-34.
51. Parkinson JR, Hyde MJ, Gale C, Santhakumaran S, Modi N. Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis. *Pediatrics*. 2013;131(4):e1240-63.
52. Davis EF, Lewandowski AJ, Aye C, Williamson W, Boardman H, Huang RC, et al. Clinical cardiovascular risk during young adulthood in offspring of hypertensive pregnancies: insights from a 20-year prospective follow-up birth cohort. *BMJ Open*. 2015;5(6):e008136.
53. Lewandowski AJ, Bradlow WM, Augustine D, Davis EF, Francis J, Singhal A, et al. Right ventricular systolic dysfunction in young adults born preterm. *Circulation*. 2013;128(7):713-20.
54. Lewandowski AJ, Augustine D, Lamata P, Davis EF, Lazdam M, Francis J, et al. Preterm heart in adult life: cardiovascular magnetic resonance reveals distinct differences in left ventricular mass, geometry, and function. *Circulation*. 2013;127(2):197-206.
55. Boardman H, Birse K, Davis EF, Whitworth P, Aggarwal V, Lewandowski AJ, et al. Comprehensive multi-modality assessment of regional and global arterial structure and function in adults born preterm. *Hypertens Res*. 2016;39(1):39-45.
56. Bensley JG, Stacy VK, De Matteo R, Harding R, Black MJ. Cardiac remodelling as a result of pre-term birth: implications for future cardiovascular disease. *Eur Heart J*. 2010;31(16):2058-66.
57. Aye CYL, Lewandowski AJ, Lamata P, Upton R, Davis E, Ohuma EO, et al. Disproportionate cardiac hypertrophy during early postnatal development in infants born preterm. *Pediatr Res*. 2017.
58. Bertagnolli M, Huyard F, Cloutier A, Anstey Z, Huot-Marchand JE, Fallaha C, et al. Transient neonatal high oxygen exposure leads to early adult cardiac dysfunction, remodeling, and activation of the renin-angiotensin system. *Hypertension*. 2014;63(1):143-50.
59. Bertagnolli M, Dios A, Beland-Bonenfant S, Gascon G, Sutherland M, Lukaszewski MA, et al. Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. *Hypertension*. 2016;67(4):774-82.
60. Entman ML, Youker K, Shoji T, Kukielka G, Shappell SB, Taylor AA, et al. Neutrophil induced oxidative injury of cardiac myocytes. A compartmented system requiring CD11b/CD18-ICAM-1 adherence. *J Clin Invest*. 1992;90(4):1335-45.
61. Raeburn CD, Sheppard F, Barsness KA, Arya J, Harken AH. Cytokines for surgeons. *Am J Surg*. 2002;183(3):268-73.
62. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. *J Mol Cell Cardiol*. 1996;28(8):1631-9.
63. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. *Lancet*. 2004;363(9404):203-9.
64. Flynn A, Chokkalingam Mani B, Mather PJ. Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. *Heart Fail Rev*. 2010;15(6):605-11.

65. Hensler ME, Miyamoto S, Nizet V. Group B streptococcal beta-hemolysin/cytolysin directly impairs cardiomyocyte viability and function. *PloS one*. 2008;3(6):e2446.
66. Wray GM, Foster SJ, Hinds CJ, Thiemermann C. A cell wall component from pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. *Shock*. 2001;15(2):135-42.
67. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. *N Engl J Med*. 2008;359(2):158-65.
68. Ishikawa T, Jou CJ, Nogami A, Kowase S, Arrington CB, Barnett SM, et al. Novel mutation in the alpha-myosin heavy chain gene is associated with sick sinus syndrome. *Circ Arrhythm Electrophysiol*. 2015;8(2):400-8.
69. Christoffels VM, Habets PE, Franco D, Campione M, de Jong F, Lamers WH, et al. Chamber formation and morphogenesis in the developing mammalian heart. *Dev Biol*. 2000;223(2):266-78.
70. Christoffels VM, Hoogaars WM, Tessari A, Clout DE, Moorman AF, Campione M. T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. *Dev Dyn*. 2004;229(4):763-70.
71. Thornburg K, Jonker S, O'Tierney P, Chattergoon N, Louey S, Faber J, et al. Regulation of the cardiomyocyte population in the developing heart. *Prog Biophys Mol Biol*. 2011;106(1):289-99.
72. Houweling AC, van Borren MM, Moorman AF, Christoffels VM. Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. *Cardiovasc Res*. 2005;67(4):583-93.
73. Iwata M, Cowling RT, Yeo SJ, Greenberg B. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. *J Mol Cell Cardiol*. 2011;51(4):542-7.
74. Tian X, Hu T, Zhang H, He L, Huang X, Liu Q, et al. Vessel formation. De novo formation of a distinct coronary vascular population in neonatal heart. *Science (New York, NY)*. 2014;345(6192):90-4.
75. McAdams RM, Vanderhoeven J, Beyer RP, Bammler TK, Farin FM, Liggitt HD, et al. Choriodecidual infection downregulates angiogenesis and morphogenesis pathways in fetal lungs from *Macaca nemestrina*. *PloS one*. 2012;7(10):e46863.
76. Parry S, Strauss JF, 3rd. Premature rupture of the fetal membranes. *N Engl J Med*. 1998;338(10):663-70.
77. Lannon SM, Vanderhoeven JP, Eschenbach DA, Gravett MG, Adams Waldorf KM. Synergy and interactions among biological pathways leading to preterm premature rupture of membranes. *Reproductive sciences (Thousand Oaks, Calif)*. 2014;21(10):1215-27.
78. Romero R, Miranda J, Chaemsathong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med*. 2015;28(12):1394-409.
79. Arnon S, Litmanovitz I, Regev R, Lis M, Shainkin-Kestenbaum R, Dolfon T. The prognostic virtue of inflammatory markers during late-onset sepsis in preterm infants. *J Perinat Med*. 2004;32(2):176-80.

80. Francis F, Bhat V, Mondal N, Adhisivam B, Jacob S, Dorairajan G, et al. Fetal inflammatory response syndrome (FIRS) and outcome of preterm neonates - a prospective analytical study. *J Matern Fetal Neonatal Med.* 2017;1-5.
81. Bohrer B, Silveira RC, Neto EC, Procianoy RS. Mechanical ventilation of newborns infant changes in plasma pro- and anti-inflammatory cytokines. *J Pediatr.* 2010;156(1):16-9.
82. Lavoie PM, Lavoie JC, Watson C, Rouleau T, Chang BA, Chessex P. Inflammatory response in preterm infants is induced early in life by oxygen and modulated by total parenteral nutrition. *Pediatr Res.* 2010;68(3):248-51.
83. Vento M, Moro M, Escrig R, Arruza L, Villar G, Izquierdo I, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. *Pediatrics.* 2009;124(3):e439-49.
84. Lee SE, Romero R, Jung H, Park CW, Park JS, Yoon BH. The intensity of the fetal inflammatory response in intraamniotic inflammation with and without microbial invasion of the amniotic cavity. *Am J Obstet Gynecol.* 2007;197(3):294 e1-6.
85. Adams Waldorf KM, McAdams RM. Influence of infection during pregnancy on fetal development. *Reproduction.* 2013;146(5):R151-62.
86. O'Tierney PF, Anderson DF, Faber JJ, Louey S, Thornburg KL, Giraud GD. Reduced systolic pressure load decreases cell-cycle activity in the fetal sheep heart. *Am J Physiol Regul Integr Comp Physiol.* 2010;299(2):R573-8.
87. Giussani DA, Camm EJ, Niu Y, Richter HG, Blanco CE, Gottschalk R, et al. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. *PloS one.* 2012;7(2):e31017.
88. Lewandowski AJ, Lazdam M, Davis E, Kyliantiras I, Diesch J, Francis J, et al. Short-term exposure to exogenous lipids in premature infants and long-term changes in aortic and cardiac function. *Arterioscler Thromb Vasc Biol.* 2011;31(9):2125-35.
89. Lewandowski AJ, Lamata P, Francis JM, Piechnik SK, Ferreira VM, Boardman H, et al. Breast Milk Consumption in Preterm Neonates and Cardiac Shape in Adulthood. *Pediatrics.* 2016;138(1).
90. Redline RW, Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. *Pediatr Dev Pathol.* 2003;6(5):435-48.

Table 1. Fetal Cytokines, Pregnancy Outcomes and Amniotic Fluid Cultures

Group	Fetal Plasma Peak (pg/ml)		Chorio- amnionitis	Preterm Labor	Peak AF Cultures (CFU)
	IL-6	IL-8			
E. coli 1	29,293.7	2,273.1	Acute Severe	YES	1.4 x 10 <sup>7</sup>
GBS 1	2,152.6	3,265.6	Acute Severe	NO	1.0 x 10 <sup>7</sup>
GBS 2	1,015.5	1,634.1	Acute Severe	YES	9.4 x 10 <sup>7</sup>
GBS 3	254.4	6,307.5	Acute Severe	YES	2.5 x 10 <sup>7</sup>
GBS 4	156.8	3,341.7	Acute Severe	YES	2.9 x 10 <sup>7</sup>
Saline 1	*	*	NO	NO	No growth
Saline 2	2.0	523.4	NO	NO	No growth
Saline 3	*	*	NO	NO	No growth
Saline 4	0.9	182.3	NO	NO	No growth
Saline 5	2.3	223.0	NO	NO	No growth

Table presents the mean (SEM) for amniotic fluid and fetal plasma peak cytokines.

Histopathologic evidence of inflammation in the placental membranes (chorioamnionitis) was diagnosed using Redline criteria.(90)

\*In two saline controls, fetal plasma was not obtained.

With the exception of E. coli 1, remaining data in this table has been previously published(26-28) and is presented to provide context for the fetal cardiac transcriptomics and cytokine data.

Table 2. Select differentially expressed probe sets in the fetal heart of animals developing the fetal inflammatory response syndrome versus saline controls

Probe ID	Gene Name	Symbol	ANOVA Model		IL-6 Model	
			Log2 Fold Change	p value	Model Coefficient*	p value
13782964	Myosin Heavy Chain 6	MYH6	-2.72	0.05**	-0.47	2.0 x 10 <sup>-5</sup>
13728400	Secreted frizzled-related protein 4	SFRP4	-2.13	0.002	-0.28	1.6 x 10 <sup>-5</sup>
13746553	Phospholipase A2, Group VII	PLA2G7	-1.58	0.02	-0.23	8.8 x 10 <sup>-4</sup>
13807788	Glutamate receptor, Ionotropic, AMPA 3	GRIA3	-1.53	7 x 10 <sup>-4</sup>	-0.19	3.3 x 10 <sup>-5</sup>
13593196	Natriuretic peptide A	NPPA	-1.51	0.001	-0.14	0.01
13789400	Collectin sub-family member 10	COLEC10	-1.49	0.002	-0.14	0.02
13728244	Myosin regulatory light chain 2, atrial isoform-like	MYL7	-1.49	0.005	-0.19	5.5 x 10 <sup>-4</sup>
13580672	Angiopoietin-like 7	ANGPTL7	-1.35	0.002	-0.1	0.005
13765171	Iroquois homeobox 4	IRX4	1.16	8 x 10 <sup>-4</sup>	0.11	0.008
13729406	STEAP family member 4	STEAP4	1.20	9 x 10 <sup>-4</sup>	0.14	6.1 x 10 <sup>-4</sup>
13730121	Cystic fibrosis transmembrane conductance regulator	CFTR	1.44	8 x 10 <sup>-4</sup>	0.18	5.5 x 10 <sup>-5</sup>
13593639	Phospholipase A2, Group IIA	PLA2G2	1.50	0.04	0.19	0.01
13809224	Angiotensin I converting enzyme 2	ACE2	1.75	0.009	0.12	0.1**
13690264	Family with sequence similarity 9, member c	FAM69C	1.84	0.004	0.17	0.02
13599257	S100 calcium binding protein A8	S100A8	2.64	0.004	0.30	0.001

\*The model coefficient estimates the log change in gene expression for a doubling of fetal plasma IL-6 concentration.

\*\*NS, nonsignificant

Table 3. Select differentially expressed gene sets and Ingenuity Pathway Analysis pathways downregulated in the fetal heart of animals with the fetal inflammatory response syndrome

<b>Gene Set Analysis</b>			
<b>Gene Set</b>	<b>Number of Genes</b>		<b>p value</b>
Cellular Morphogenesis During Differentiation	37		0.008
Axonogenesis	31		0.008
Neurite Development	40		0.008
Neuron Differentiation	57		0.008
Neuron Development	46		0.008
Nervous System Development	292		0.01
Regulation of DNA Replication	16		0.03
Hallmark TGF Beta Signaling	41		0.04
Negative Regulation of Cellular Component Organization and Biogenesis	23		0.04
<b>Ingenuity Pathway Functional Analysis of a Network*</b>			
<b>Diseases and Biological Functions</b>	<b>Number of Molecules</b>		<b>p value</b>
Cellular Movement, Migration of Cells	150		$7 \times 10^{-21}$
Development of Vasculature	94		$2 \times 10^{-15}$
Morphology of Blood Vessel	40		$1 \times 10^{-13}$
Proliferation of Smooth Muscle Cells	36		$3 \times 10^{-12}$
Growth of Muscle Tissue	42		$1 \times 10^{-11}$
Morphology of Cardiovascular System	69		$4 \times 10^{-11}$
Vasculogenesis	66		$1 \times 10^{-10}$
Abnormal Morphology of Cardiovascular System	50		$5 \times 10^{-10}$
Migration of Endothelial Cells	33		$4 \times 10^{-8}$
<b>Ingenuity Pathway Transcription Factor Analysis**</b>			
<b>Top Transcription Factors</b>	<b>Predicted Activation State</b>	<b>Activation Z-Score</b>	<b>p-value of overlap</b>
TNF	Activated	4.2	$2 \times 10^{-14}$
IL1B	Activated	3.7	$1 \times 10^{-11}$
TGFB1	Inhibited	-2.0	$2 \times 10^{-10}$

Gene Set and Ingenuity Pathway Analyses were based on the IL-6 model and select results are reported in the table.

\*The Ingenuity Pathway Functional Analysis of a Network identified biological functions and/or diseases most significant to the molecules in the network using a right-tailed Fisher's exact test.

\*\*Transcription factor analysis is based on prior knowledge of expected effects between transcription factors and their target genes stored in the Ingenuity Pathway Analysis library. The overlap p-value measures whether there is a statistically significant overlap between the dataset genes and the genes regulated by a transcription factor using Fisher's Exact Test.

## Figure Legends.

Figure 1. Bacterial quantities, cytokines and gene expression in fetal heart tissues. (A) Quantitation of bacterial and cytokine protein levels in the fetal heart. Quantities of GBS and fetal cardiac cytokines in cases with the fetal inflammatory response syndrome (N=4, GBS) and controls (N=4) are shown (\*,  $p < 0.05$ ). FIRS: fetal inflammatory response syndrome, CFU: colony forming units. (B, C) Hematoxylin and eosin staining of fetal cardiac tissues is shown to demonstrate cytoplasmic pallor, but otherwise an absence of neutrophilic infiltrates or significant inflammation in *E. coli* 1 (B) versus Saline 3 (C). (D) Comparison of the microarray and qRT-PCR analysis. The x-axis represents individual genes and the y-axis fold-change in expression by either microarray (gray bars) or qRT-PCR (black bars). All genes shown were significant in the unadjusted microarray analysis. Eight of ten genes selected for validation by qRT-PCR (black bars) were significantly up- or downregulated (\*,  $p < 0.05$ ; two-sided t-test). (E) A heatmap depicting gene expression for the “cellular morphogenesis during differentiation” gene set is shown ( $p = 0.008$ ; Table 3).

Figure 2. (A) Heatmap of gene expression for the Ingenuity Pathway Analysis gene set, “morphology of cardiovascular system”, is shown across all samples. The rows represent genes and the columns represent either fetal inflammatory response syndrome cases (red) or controls (blue). (B) A visual construct of the “morphology of cardiovascular system” gene set depicts the regulatory network of genes identified in the nonhuman primate fetal cardiac tissues. “Morphology of cardiovascular system” was a significantly downregulated gene set identified through Ingenuity Pathway Analysis in the IL-6 model ( $p = 4 \times 10^{-11}$ , right-tailed Fisher’s exact test). Each node represents a gene with different colored lines showing types of connectivity and functional relationships. Green and red nodes represent significant gene down- and up-regulation, respectfully. Protein-protein interactions from the Ingenuity Knowledge base were used to connect genes. Network data was then exported into cytoscape (version 3.2.1) to make custom network figures.

Figure 3. Conceptual model of events leading to fetal cardiac injury *in utero*. First, bacteria from the vagina traffic into the choriodecidual space, modeled in our experiments by inoculation of bacteria into this space using an implanted catheter in a nonhuman primate. Inflammatory cytokines are then produced by the decidua and chorioamniotic membranes, which diffuse into the amniotic fluid and fetal lung leading to a placental and fetal inflammatory response. When fetal inflammation is severe, which is typical in cases of early preterm birth complicated by infection, disruptions in the expression of gene networks for morphogenesis and vasculogenesis may occur in the fetal heart.